PRESS RELEASE
16 November 2023

Cell And Gene Therapies And Section 112: An Overview Of The State Of §112 Law And Considerations For Developers Of Cell And Gene Therapies

GP
Goodwin Procter LLP

Contributor

At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.
The analysis of patent protection is an integral part of the development process for cell and gene therapies.
United States
To print this article, all you need is to be registered or login on Mondaq.com.

November 29, 2023 | 1:00 PM - 2:00 PM ET

SUMMARY

The analysis of patent protection is an integral part of the development process for cell and gene therapies. In a field where the complexity of patent portfolios and patent claims reflects the complexity of the science, the requirements of 35 U.S.C. § 112 may be critical to defending or challenging the patentability of various aspects of these therapies. Join us as we discuss the state of the law regarding §112, its implications for the types of claims that might apply to cell and gene therapies, and considerations for patent prosecution and challenges in this growing field.

Robert Frederickson, Alexandra Lu and Sabrina Poulos will host this webinar.

REGISTER

PRESS RELEASE
16 November 2023

Cell And Gene Therapies And Section 112: An Overview Of The State Of §112 Law And Considerations For Developers Of Cell And Gene Therapies

United States

Contributor

At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More